“…RS is a severe event occurring in 10-15% of CLL patients. 15,50 Very few studies have investigated the features that at CLL diagnosis may TL ≤5000 bp 9/62 18.9% Figure 4 Telomere length (TL) as a predictor for transformation to Richter's syndrome (RS). The 5-year cumulative risk of transformation was 18.9% in patients with TLp5000 bp, as opposed to 6.4% for those with long telomeres.…”
“…RS is a severe event occurring in 10-15% of CLL patients. 15,50 Very few studies have investigated the features that at CLL diagnosis may TL ≤5000 bp 9/62 18.9% Figure 4 Telomere length (TL) as a predictor for transformation to Richter's syndrome (RS). The 5-year cumulative risk of transformation was 18.9% in patients with TLp5000 bp, as opposed to 6.4% for those with long telomeres.…”
“…4 RS carries a dismal prognosis. In the historical experience of our institution, disease control can only be obtained in a fraction of patients and is of brief duration (complete response rates of 0% to 25%, failure-free survival of 1.3 to 5 months, and overall survival [OS] of 2.2 to 8.5 months).…”
Key Points
Histologically aggressive CLL differs from histologically indolent CLL. Patients with different CLL phases but similar SUVmax have similar outcomes. FDG/PET is a useful diagnostic tool for patients with CLL and suspected transformation.
“…85 The large cells of RS either arise through a transformation of the original CLL clone by the acquisition of new genetic abnormalities or less frequently represent a new secondary neoplasm. The clinical outcome of the disease is generally poor, with median survival of months from transformation, but prognosis is better when transformation occurs in previously untreated patients.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.